Compass Pathways plc (CMPS) — Capitalizing on its positive Phase 3 readouts, Compass priced a public offering of 17.5 million American Depositary Shares at $8.00 each, plus pre-funded warrants, for expected gross proceeds of about $150 million (before a 30-day over-allotment option for up to ~2.8 million more ADSs).
Proceeds are earmarked for its ongoing COMP005/COMP006 trials, a Phase 2b/3 PTSD study, and commercial-readiness activities. The raise strengthened Compass's balance sheet ahead of its planned regulatory filing.
Source: businesswire.com
For the rest of that week's sector news, read our week in review.